JP2017507142A5 - - Google Patents

Download PDF

Info

Publication number
JP2017507142A5
JP2017507142A5 JP2016553284A JP2016553284A JP2017507142A5 JP 2017507142 A5 JP2017507142 A5 JP 2017507142A5 JP 2016553284 A JP2016553284 A JP 2016553284A JP 2016553284 A JP2016553284 A JP 2016553284A JP 2017507142 A5 JP2017507142 A5 JP 2017507142A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
administered
fgf
cartilage
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016553284A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017507142A (ja
JP6431082B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2015/053631 external-priority patent/WO2015124731A1/en
Publication of JP2017507142A publication Critical patent/JP2017507142A/ja
Publication of JP2017507142A5 publication Critical patent/JP2017507142A5/ja
Application granted granted Critical
Publication of JP6431082B2 publication Critical patent/JP6431082B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016553284A 2014-02-20 2015-02-20 Fgf−18化合物の投与計画 Active JP6431082B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14000600.8 2014-02-20
EP14000600 2014-02-20
PCT/EP2015/053631 WO2015124731A1 (en) 2014-02-20 2015-02-20 Fgf-18 compound dosing regimen

Publications (3)

Publication Number Publication Date
JP2017507142A JP2017507142A (ja) 2017-03-16
JP2017507142A5 true JP2017507142A5 (enExample) 2018-03-01
JP6431082B2 JP6431082B2 (ja) 2018-11-28

Family

ID=50151088

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016553329A Active JP6431083B2 (ja) 2014-02-20 2015-02-20 Fgf−18化合物の投与計画
JP2016553284A Active JP6431082B2 (ja) 2014-02-20 2015-02-20 Fgf−18化合物の投与計画

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2016553329A Active JP6431083B2 (ja) 2014-02-20 2015-02-20 Fgf−18化合物の投与計画

Country Status (25)

Country Link
US (2) US9724388B2 (enExample)
EP (2) EP3107559B1 (enExample)
JP (2) JP6431083B2 (enExample)
KR (2) KR102410986B1 (enExample)
CN (2) CN106456713A (enExample)
AR (2) AR099558A1 (enExample)
AU (2) AU2015220777B2 (enExample)
BR (2) BR112016018685A2 (enExample)
CA (1) CA2938791A1 (enExample)
DK (2) DK3119417T3 (enExample)
ES (2) ES2689071T3 (enExample)
HR (2) HRP20181572T1 (enExample)
HU (1) HUE040350T2 (enExample)
IL (2) IL247083B (enExample)
LT (2) LT3107559T (enExample)
MX (2) MX2016010872A (enExample)
NZ (1) NZ723148A (enExample)
PL (2) PL3119417T3 (enExample)
PT (2) PT3119417T (enExample)
RS (2) RS57853B1 (enExample)
RU (2) RU2700582C2 (enExample)
SG (2) SG11201606505UA (enExample)
SI (2) SI3107559T1 (enExample)
WO (2) WO2015124731A1 (enExample)
ZA (2) ZA201605547B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20181573T1 (hr) 2014-02-20 2018-11-30 Merck Patent Gmbh Implantat koji sadrži fgf-18
JP6431083B2 (ja) 2014-02-20 2018-11-28 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung Fgf−18化合物の投与計画
CA2971315C (en) 2015-01-29 2023-02-14 Ares Trading S.A. Immunoassays for high positively charged proteins
ES2878575T3 (es) 2016-02-22 2021-11-19 Novartis Ag Métodos para usar agonistas del FXR
DK3687558T3 (da) 2017-09-29 2022-06-20 Merck Patent Gmbh Metaboliske biomarkører til forudsigelse af modtageligheden på fgf-18 forbindelse
DK3688468T3 (da) * 2017-09-29 2022-06-20 Merck Patent Gmbh Inflammatoriske biomarkører til forudsigelse af modtageligheden for fgf-18 forbindelse
IL281333B2 (en) 2018-09-10 2025-11-01 Merck Patent Gmbh A method for reducing risk in a clinical trial
AU2020218844A1 (en) * 2019-02-08 2021-08-19 Merck Patent Gmbh Treatment of patients at risk of rapid progression of osteoarthritis
KR102920449B1 (ko) * 2023-03-29 2026-02-03 주식회사 아이프로테인테라퓨틱스 인터류킨-1 수용체 길항제 변이체 및 이의 용도
WO2025077768A1 (en) * 2023-10-11 2025-04-17 Sichuan Real & Best Biotech Co., Ltd. Compositions and methods for treating arthritis

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040136970A1 (en) * 2002-10-07 2004-07-15 Ellsworth Jeff L. Methods for administering FGF18
ES2706848T3 (es) 2004-07-06 2019-04-01 Zymogenetics Inc Composición farmacéutica que comprende FGF18 y antagonista de IL-1 y método de uso
AU2006326870A1 (en) * 2005-12-22 2007-06-28 Apollo Life Sciences Transdermal delivery of pharmaceutical agents
MY148277A (en) * 2006-08-25 2013-03-29 Ares Trading Sa Treatment of cartilage disorders with fgf-18
KR101419961B1 (ko) 2006-08-25 2014-07-30 아레스 트레이딩 에스.에이. Fgf-18 로 연골 질환의 치료
DE102006043260A1 (de) * 2006-09-11 2008-03-27 Krones Ag Etikettieranlage
CN103547580B (zh) * 2011-03-22 2016-12-07 阿迪维纳斯疗法有限公司 取代的稠合三环化合物、其组合物及医药用途
BR112016018704B1 (pt) 2014-02-20 2021-01-05 Merck Patent Gmbh processo para produção de um material de cartilagem transplantável para engenharia de tecido
HRP20181573T1 (hr) 2014-02-20 2018-11-30 Merck Patent Gmbh Implantat koji sadrži fgf-18
JP6431083B2 (ja) 2014-02-20 2018-11-28 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung Fgf−18化合物の投与計画

Similar Documents

Publication Publication Date Title
JP2017512194A5 (enExample)
JP2012193216A5 (enExample)
FI3936130T3 (fi) Valbenatsiinin annostusohjelma hyperkineettisten liikehäiriöiden hoitoon
MX2017004592A (es) Formulaciones farmaceuticas para la administracion oral de farmacos peptidicos o proteinicos.
JP2015517488A5 (enExample)
JP2015057451A5 (enExample)
MX2018008021A (es) Metodos y composiciones para el tratamiento de trastornos relacionados con convulsiones.
HK1221646A1 (zh) 高剂量普利多匹定用於治疗亨廷顿舞蹈症的用途
JP2013231087A5 (enExample)
JP2015038135A5 (enExample)
RU2016137289A (ru) Схема применения соединения fgf-18
WO2015171965A3 (en) Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo
HRP20230300T1 (hr) Kombinacije imetelstata i venetoklaksa za liječenje akutne mijeloidne leukemije
JP2017503014A5 (enExample)
JP2016539125A5 (enExample)
JP2016534081A5 (ja) ゾレドロン酸の増強された経口バイオアベイラビリティーを有する経口剤形を調製する方法
JP2013541583A5 (enExample)
JP2016530291A5 (enExample)
JP2015522603A5 (enExample)
JP2017507145A5 (enExample)
JP2016512247A5 (enExample)
JP2017061488A5 (enExample)
HRP20161796T1 (hr) Farmaceutski pripravak za primjenu u tretmanu ili prevenciji deficijencije vitamina i minerala kod pacijenata podvrgnutih operaciji želučane premosnice
EP4474012A3 (en) Melatonin mini-tablets and method of manufacturing the same
JP2017531042A5 (enExample)